Calanus Oil Supplementation and Maximal Oxygen Uptake

Healthy Clinical Trial

Official title:

Effect of Copepod Oil Supplementation (Calanus Finmarchicus) on Endurance and VO2max in Healthy Obese Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02908828
• Other study ID #: 2015/2303
• Status: Completed
• Phase: N/A
• Start date: October 2016
• Est. completion date: September 19, 2017

Study information

• Verified date: September 2020
• Source: Norwegian University of Science and Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Copepod oil is extracted from the marine copepod Calanus finmarchicus, the dominant plankton species in the marine food web in the Norwegian Sea. Copepods constitute the largest renewable and harvestable resource in the Norwegian Sea and adjacent waters, and it is now developed knowledge and technology for sustainable harvesting of this "new" resource. The purpose of this study is to investigate whether Calanus copepod oil supplementation has an equivalent effect on maximal oxygen uptake in humans to that seen in experimental studies in mice.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. completion date: September 19, 2017
• Est. primary completion date: September 19, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 50 Years

Eligibility

Inclusion Criteria:

• in good health

• Body mass index (BMI) between 18,5 and 29,9

Exclusion Criteria:

• Medical condition limiting VO2max (COPD or asthma).

• diagnosed coronary artery disease

• Any other significant medical condition

• medication effecting exercise capacity (e.i. betablockers)

• Pregnancy

• Participation in other clinical trials

• Shellfish allergies

• Systolic blood pressure > 170 mmHG, or diastolic BP > 105 mmHG.

• contraindications for maximal exercise testing

Related Conditions & MeSH terms

• Healthy

Intervention

Dietary Supplement:
• Calanus oil

• placebo dietary oil

Locations

Country	Name	City	State
Norway	Institutt for Medisinsk Biologi, UiT Norges arktiske universitet	Tromsø
Norway	KG Jebsen-senter for Hjertetrening, NTNU	Trondheim

Sponsors (3)

Lead Sponsor	Collaborator
Norwegian University of Science and Technology	Calanus, University of Tromso

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	maximal oxygen uptake (VO2max)	Measured with indirect calorimetry at a treadmill (running/walking) with gradually increasing work load until exhaustion. After 10-15 min with warmup at 70% of maximal heart rate, work load will be increased every 1-2 minute and the changes maximal oxygen uptake (VO2) will be recorded automatically.	6 months
Secondary	Body composition (InBody, Japan)		6 months
Secondary	Self-reported physical activity	assessed with International Physical Activity Questionnaire (IPAQ) short version	6 months